Tuesday, May 29

08:30-12:30

Symposium IV

Ovarian Cancer Genetics and Epigenetics: from the Lab to the Clinic

11:00-12:30

Selected Oral Presentations from Scientific Abstracts

OC-04.01
OVARIAN CANCER SURVIVAL FOR WOMEN WITH A BRCA1 OR BRCA2 MUTATION
Joel Moody ¹; John McLaughlin ¹; Barry Rosen ²; Harvey Risch ³; Isabel Fan ¹; Patricia Shaw ⁴; Steven Narod ^5
1Samuel Lunenfeld Research Institute, Toronto, ON, Canada; ²Department of Gynecology, Princess Margaret Hospital, Toronto, ON, Canada; ³Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, United States; ⁴Department of Pathology, Princess Margaret Hospital, Toronto, ON, Canada; ⁵Women’s College Research Institute, Toronto, ON, Canada

OC-04.02
RIBOSOME BIOGENESIS AS A NOVEL TARGET OF ANTI-CANCER DRUGS
Tom Moss ; Nourdine Hamdane ; Frédéric Lessard ; Victor Stefanovsky
Cancer Research Centre, Laval University, Quebec, QC, Canada

OC-04.03
FUNCTIONS OF PALB2 IN GENOMIC STABILITY: IMPLICATIONS FOR BREAST AND OVARIAN CANCER
Jean-Yves Masson ; Joris Pauty ; Rémi Buisson
Laval University Cancer Research Center, Quebec, QC, Canada

OC-04.04
HIGH GRADE SEROUS CARCINOMAS WITH OVARIAN AND ENDOMETRIAL INVOLVEMENT: ASSESSMENT OF CLINICAL CHARACTERISTICS, IMMUNOPHENOTYPE, AND SITE OF ORIGIN, AS A STEP TOWARDS A BETTER CLASSIFICATION SYSTEM
Mina Wesa ¹; Osama Al-Agha ²; Shannon Salvador ²; Steve E. Kalloger ²; Jen Santos ²; David G. Huntsman ²; C. Blake Gilks ²; Jessica N. McAlpine ^2
1Gyn/Obs, Div Gyn Oncology, UBC and BCCA; ²UBC; Vancouver, BC, Canada

OC-04.05
OVARIAN CANCER ASCITES INCREASE MCL-1 EXPRESSION THROUGH THE ERK1/2-ELK1 SIGNALING TO ATTENUATE TRAIL-INDUCED APOPTOSIS
Nadzeya Goncharenko Khaider ; Denis Lane ; Claudine Rancourt ; Alain Piché
Université de Sherbrooke, Sherbrooke, QC, Canada

OC-04.06
THE 5'-AMP-ACTIVATED PROTEIN KINASE (AMPK) PATHWAY IS UPREGULATED IN OVARIAN CANCER SPHEROIDS TO PROMOTE THE DORMANT PHENOTYPE
Teresa Peart ; Rohann Correa ; Gabriel DiMattia ; Trevor Shepherd
University of Western Ontario, London, ON, Canada

12:30-14:30

Lunch and Poster Session III

12:30-13:00

Lunch Break

13:00-14:30

Poster Sessions

P.03
ANTI-VEGF-A THERAPY REDUCES TUMOR GROWTH AND EXTENDS SURVIVAL IN A MURINE MODEL OF OVARIAN GRANULOSA CELL TUMORS
Mayra Tsoi ¹; Marie-Noëlle Laguë ²; Alexandre Boyer ²; Marilène Paquet ³; Marie-Ève Nadeau ²; Derek Boerboom ^2
1University of Montreal - Faculty of Veterinary Medicine, St-Hyacinthe, QC, Canada; ²University of Montreal, St-Hyacinthe, QC, Canada; ³McGill University, Montreal, QC, Canada

P.06
OSTEOPROTEGERIN (OPG) CONTRIBUTES TO CELL SURVIVAL IN OVARIAN CANCER
Denis Lane ; Isabelle Matte ; Claudine Rancourt ; Alain Piché
Departement de Microbiologie et Infectiologie, FMSS, Université de Sherbrooke, Sherbrooke, QC, Canada

P.09
TARGETING ESTROGEN RECEPTOR ALPHA IN HORMONE-DEPENDENT OVARIAN CANCER USING NOVEL ESTRADIOL-PLATINUM(II) HYBRIDS
Kevin Brasseur ; Valérie Leblanc ; François Fabi ; Sophie Parent ; Caroline Descôteaux ; Gervais Bérubé ; Éric Asselin
Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada

P.12
THE CHOLESTEROL BIOSYNTHETIC PATHWAY MEDIATES THE INCREASED TUMORIGENICITY OF METASTATIC EPITHELIAL OVARIAN CANCER CELLS
James Greenaway ; Rebecca Smith ; Jim Petrik
University of Guelph, Guelph, ON, Canada

P.15
EMT TRANSCRIPTION FACTORS, SNAIL AND SLUG, CONTRIBUTE TO CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER
Alexandria Haslehurst ¹; Madhuri Koti ¹; Moyez Dharsee ²; Joseph Geraci ²; Johanne Weberpals ³; Jeremy Squire ¹; Paul Park ¹; Harriet Feilotter ^1
1Queen's University, Kingston, ON, Canada; ²Ontario Cancer Biomarker Network, Toronto, ON, Canada; ³Division of Gynaecologic Oncology, The Ottawa Hospital, Ottawa, ON, Canada

P.18
MECHANISMS OF RESISTANCE IN CARBOPLATIN, DOCETAXEL, AND COMBINED CARBOPLATIN/DOCETAXEL RESISTANT OVARIAN CANCER CELL LINES
Rashmi Narendrula ¹; Stephen Armstrong ¹; Baoqing Guo ²; Amadeo Parissenti ²; Stephanie Cull ²; Carita Lanner ^3
1Laurentian University; ²Health Sciences North Cancer Centre; ³Northern Ontario School of Medicine; Sudbury, ON, Canada

P.21
MECHANISMS BY WHICH ESTROGEN ACCELERATES OVARIAN TUMOR INITIATION
Nhung Vuong ; Elizabeth Macdonald ; Barbara Vanderhyden
University of Ottawa, Ottawa, ON, Canada

P.24
INCIDENCE AND PROGNOSTIC IMPACT OF HER-3 MRNA AND PROTEIN EXPRESSION IN OVARIAN CARCINOMA PATIENTS TREATED WITH PLATINUM AND PACLITAXEL
Stefan Kommoss ¹; Steve Kalloger ¹; Boris Winterhoff ²; Christine Chow ³; Blake Gilks ¹; David Huntsman ⁴; Michael Anglesio ^5
1Department of Pathology and Lab Medicine, UBC, Vancouver, BC, Canada; ²Mayo Clinic, Department of Gyn Surgery, Rochester, MN, United States; ³GPEC Lab Department of Pathology of VGH and UBC, Vancouver, BC, Canada; ⁴CTAG, BCCA and Department of Pathology and Lab Medicine, UBC, Vancouver, BC, Canada; ⁵Department of Pathology and Lab Medicine, UBC, Vancouver, BC, Canada

P.27
INDUCTION OF EPITHELIAL-MESENCHYMAL TRANSITION IN MOUSE OVIDUCTAL EPITHELIAL CELLS ENHANCES STEM CELL CHARACTERISTICS
Kholoud Alwosaibai ; Barbara Vanderhyden
Cellular and Molecular Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada

P.30
THE NEW AMINOSTEROID LOT 25B HAS AN IN VITRO AND IN VIVO ANTICANCER ACTIVITY ON THE OVARIAN CANCER CELL LINE OVCAR-3
Lucie Carolle Kenmogne ; Jenny Roy ; René Maltais ; Donald Poirier
Laboratory of Medicinal Chemistry, CHUQ/CHUL-Research Center and Faculty of Medicine, Laval University, Quebec, QC, Canada

P.33
INVESTIGATING THE MECHANISMS FOR RESTRICTIVE MYXOMA VIRUS-MEDIATED ONCOLYSIS IN EPITHELIAL OVARIAN CANCER SPHEROIDS
Jessica Tong ¹; Grant McFadden ²; Gabriel DiMattia ³; Trevor Shepherd ^3
1University of Western Ontario, London, ON, Canada; ²University of Florida, Gainesville, FL, United States; ³University of Western Ontario, London, ON, Canada

P.36
SURVIVORSHIP IN OVARIAN CANCER: A PILOT STUDY TO ASSESS THE DIVERSE NEEDS OF OVARIAN CANCER SURVIVORS
Flora F. Teng ¹; Barbara Yermen ²; Lisa J Boretta ²; Elaine Chan ²; Janice M. Hu ²; Karen Sill ³; Tracy Kolwich ²; Elisabeth Ross ²; Lori A. Brotto ¹; Jessica N. McAlpine ^1
1University of British Columbia; ²Ovarian Cancer Canada; ³BC Cancer Agency; Vancouver, BC, Canada

P.39
AN INTERIM ANALYSIS OF THE CANADIAN OVARIAN CANCER SURVIVORSHIP SURVEY
Steve Kalloger ¹; Elisabeth Ross ²; Paul Hoskins ³; Anna Tinker ^3
1University of British Columbia, Vancouver, BC, Canada; ²Ovarian Cancer Canada, Toronto, ON, Canada; ³British Columbia Cancer Agency, Vancouver, BC, Canada

P.42
SUPRESSED OPA1 PROCESSING AND MITOCHONDRIAL FISSION IN CHEMORESISTANCE IN OVARIAN CANCER CELLS
Bao Kong ¹; Ella Fung ²; Heidi McBride ³; Ruth Slack ²; Benjamin Tsang ^2
1University of Ottawa & Ottawa Hospital Research Institute, Ottawa, ON, Canada; ²University of Ottawa, Ottawa, ON, Canada; ³McGill University, Montreal, QC, Canada

P.45
THE DIAGNOSTIC UTILITY OF P53/P16 TO DISTINGUISH HIGH-GRADE FROM LOW-GRADE SEROUS CARCINOMA
Martin Köbel ¹; Alon Altman ²; Gregg Nelson ³; Guangming Han ^1
1University of Calgary, Calgary, AB, Canada; ²Winnipeg Health Sciences Center, Winnipeg, MB, Canada; ³Tom Baker Cancer Centre, Calgary, AB, Canada

P.48
TANDEM INHIBITION OF C-MET, C-SRC, THE EPIDERMAL GROWTH FACTOR (EGFR) AND INDUCTION OF DNA DAMAGE: A NOVEL APPROACH TO DRUG DISCOVERY AGAINST ADVANCED OVARIAN CANCER
Ruba Halaoui ; Anne-Laure Larroque-Lombard ; Suman Rao ; Bertrand Jean-Claude
McGill University, Montreal, QC, Canada

14:30-15:45

Discussion Forum on Endometrial and Ovarian Cancers: Similar Molecular Pathways, Different Geography

15:45- 16:30

Workshop Reports, Summary and Future Directions, Awards and Farewell